Brief: Werewolf Therapeutics To Present Data From Ongoing Phase 1/1B Clinical Trial Of Wtx-124 As Monotherapy And In Combination With Pembrolizumab In Solid Tumors

Werewolf Therapeutics

01/06/2024 14:04

Werewolf Therapeutics Inc  HOWL.O :
    * WEREWOLF THERAPEUTICS TO PRESENT DATA FROM ONGOING PHASE
1/1B
CLINICAL TRIAL OF WTX-124 AS MONOTHERAPY AND IN COMBINATION WITH
PEMBROLIZUMAB IN SOLID TUMORS
    * WEREWOLF THERAPEUTICS: WTX-124 SHOWN TO BE CLINICALLY
ACTIVE AND
GENERALLY WELL-TOLERATED IN PATIENTS

Source text for Eikon:  ID:nGNXQXklF 
Further company coverage:  HOWL.O